Investigational drug · Phase 2
AT673
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Adults With Overweight/Obesity and Type 2 Diabetes.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "AT673"
First trial start
2026
Jun 19, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AT673", any sponsor or status.
Conditions studied
As listed on its trial records.
- Adults With Overweight/Obesity and Type 2 Diabetes
Approved drugs for the same conditions: Type 2 diabetes · Obesity and weight management · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "AT673" as an intervention, largest first.
- A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or ObesityPivotal-lookingActive, not recruiting
Antag TherapeuticsIndustry
NCT07724340 · 150 participants (planned) · Start Jun 19, 2026 · Primary completion Feb 2027
Drug: AT673 low dose; AT673 high dose and 1 more · For: Adults With Overweight/Obesity and Type 2 Diabetes
Sites: Chandler, Arizona; Anaheim, California; Hollywood, Florida · 8 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.